Urine-based test detects prostate cancer with 91% accuracy: Johns Hopkins

A urine-based biomarker panel detected prostate cancer in 91% of specimens with a diagnostic accuracy of 78.6% to 85.7%, according to a study published Sept. 2 in eBioMedicine. 

Led by a team from Baltimore-based Johns Hopkins Kimmel Cancer Center and St. Petersburg, Fla.-based Johns Hopkins All Children’s Hospital, researchers developed and validated the test on samples from patients with biopsy-proven prostate cancer undergoing prostate-removal surgeries at Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center and Celebration, Fla.-based AdventHealth Global Robotics Institute.

Here are three notes on the study:

1. Researchers identified three biomarkers — TTC3, H4C5 and EPCAM — that identify the presence of prostate cancer in urine samples.
2. The test accurately identified prostate cancer 91% of the time and accurately ruled out people without prostate cancer 84% of the time, according to a Sept. 2 news release from Johns Hopkins.
3. “This new biomarker panel offers a promising, sensitive and specific, noninvasive diagnostic test for prostate cancer,” Ranjan Perera, PhD, senior study author and director of the Center for RNA Biology at Johns Hopkins All Children’s Hospital, said in the release. “It has the potential to accurately detect prostate cancer, reduce unnecessary biopsies, improve diagnostic accuracy in PSA-negative patients, and serve as the foundation for both laboratory-developed and in vitro diagnostic assays.”

Read the full study here. 

The post Urine-based test detects prostate cancer with 91% accuracy: Johns Hopkins appeared first on Becker’s Hospital Review | Healthcare News & Analysis.